| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ryosuke Watanabe, Yukihiro Tambe, Hirokazu Inoue, Takahiro Isono, Masataka Haneda, Ken-Ichi Isobe, Toshiyuki Kobayashi, Okio Hino, Hidetoshi Okabe, Tokuhiro Chan. GADD34 inhibits mammalian target of rapamycin signaling via tuberous sclerosis complex and controls cell survival under bioenergetic stress. International journal of molecular medicine. vol 19. issue 3. 2007-03-16. PMID:17273797. |
during conditions of cell stress, gadd34 forms a stable complex with tuberous sclerosis complex (tsc) 1/2, causes tsc2 dephosphorylation, and inhibits signaling by mammalian target of the rapamycin (mtor). |
2007-03-16 |
2023-08-12 |
Not clear |
| Boyi Gan, Youngdong Yoo, Jun-Lin Gua. Association of focal adhesion kinase with tuberous sclerosis complex 2 in the regulation of s6 kinase activation and cell growth. The Journal of biological chemistry. vol 281. issue 49. 2007-01-25. PMID:17043358. |
tuberous sclerosis complex 1 (tsc1) and tsc2 tumor suppressor proteins have been shown to negatively regulate cell growth through inhibition of the mammalian target of rapamycin (mtor) pathway. |
2007-01-25 |
2023-08-12 |
Not clear |
| Cristina Malagelada, Elizabeth J Ryu, Subhas C Biswas, Vernice Jackson-Lewis, Lloyd A Green. RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 26. issue 39. 2006-11-27. PMID:17005863. |
the mechanism by which 6-ohda and rtp801 induce neuron death appears to involve repression of mammalian target of rapamycin (mtor) kinase activity, and such death is inhibited by shrnas targeting tsc2 (tuberous sclerosis complex), a protein with which rtp801 interacts to block mtor activation. |
2006-11-27 |
2023-08-12 |
Not clear |
| Edward W Arvisais, Angela Romanelli, Xiaoying Hou, John S Davi. AKT-independent phosphorylation of TSC2 and activation of mTOR and ribosomal protein S6 kinase signaling by prostaglandin F2alpha. The Journal of biological chemistry. vol 281. issue 37. 2006-10-31. PMID:16816403. |
treatment with pgf2alpha did not increase akt phosphorylation but increased the phosphorylation of erk and the tumor suppressor protein tuberous sclerosis complex 2 (tsc2), an upstream regulator of mtor. |
2006-10-31 |
2023-08-12 |
Not clear |
| Youyuan Xu, Shao-Yong Chen, Kenneth N Ross, Steven P Bal. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer research. vol 66. issue 15. 2006-09-28. PMID:16885382. |
significantly, dht stimulation of mtor was not mediated through activation of the pi3k/akt or mitogen-activated protein kinase/p90 ribosomal s6 kinase pathways and subsequent tuberous sclerosis complex 2/tuberin inactivation or by suppression of amp-activated protein kinase. |
2006-09-28 |
2023-08-12 |
Not clear |
| Xiuyun Jiang, Raymond S Yeun. Regulation of microtubule-dependent protein transport by the TSC2/mammalian target of rapamycin pathway. Cancer research. vol 66. issue 10. 2006-07-18. PMID:16707451. |
recent studies have identified tsc1 and tsc2, two tumor suppressor genes involved in tuberous sclerosis complex, as regulators of the mammalian target of rapamycin (mtor) pathway. |
2006-07-18 |
2023-08-12 |
Not clear |
| C G Prou. Regulation of protein synthesis by insulin. Biochemical Society transactions. vol 34. issue Pt 2. 2006-06-16. PMID:16545079. |
pkb also phosphorylates the tsc1 (tuberous sclerosis complex 1)-tsc2 complex to relieve its inhibitory action on the mtor (mammalian target of rapamycin). |
2006-06-16 |
2023-08-12 |
Not clear |
| Eileen Connolly, Steve Braunstein, Silvia Formenti, Robert J Schneide. Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Molecular and cellular biology. vol 26. issue 10. 2006-06-09. PMID:16648488. |
in transformed breast epithelial cells under hypoxia, the mtor and s6 kinases are constitutively activated and the mtor negative regulator tuberous sclerosis complex 2 (tsc2) protein fails to function. |
2006-06-09 |
2023-08-12 |
Not clear |
| Mark Rolfe, Laura E McLeod, Phillip F Pratt, Christopher G Prou. Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2). The Biochemical journal. vol 388. issue Pt 3. 2005-12-13. PMID:15757502. |
pe stimulation of cardiomyocytes induced the phosphorylation of tsc2 (tuberous sclerosis complex 2), a negative regulator of mtor activity. |
2005-12-13 |
2023-08-12 |
Not clear |
| Annett Hahn-Windgassen, Veronique Nogueira, Chia-Chen Chen, Jennifer E Skeen, Nahum Sonenberg, Nissim Ha. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. The Journal of biological chemistry. vol 280. issue 37. 2005-10-20. PMID:16027121. |
the known pathway by which akt activates mtor is via direct phosphorylation and inhibition of tuberous sclerosis complex 2 (tsc2), which is a negative regulator of mtor. |
2005-10-20 |
2023-08-12 |
Not clear |
| Andrew R Tee, John Blenis, Christopher G Prou. Analysis of mTOR signaling by the small G-proteins, Rheb and RhebL1. FEBS letters. vol 579. issue 21. 2005-10-03. PMID:16098514. |
in this study, we show that rheb like-1 protein (rhebl1) rescues mtor signaling during nutrient withdrawal and that tuberous sclerosis complex-1 (tsc) and tsc2 impairs rhebl1-mediated signaling through mtor. |
2005-10-03 |
2023-08-12 |
Not clear |
| R M Gemmill, M Zhou, L Costa, C Korch, R M Bukowski, H A Drabki. Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma. British journal of cancer. vol 92. issue 12. 2005-09-12. PMID:15956968. |
tuberous sclerosis mutations activate mammalian target of rapamycin (mtor) and biochemically resemble vhl alterations. |
2005-09-12 |
2023-08-12 |
Not clear |
| Avi Sofer, Kui Lei, Cory M Johannessen, Leif W Ellise. Regulation of mTOR and cell growth in response to energy stress by REDD1. Molecular and cellular biology. vol 25. issue 14. 2005-09-01. PMID:15988001. |
the tuberous sclerosis tumor suppressors tsc1 and tsc2 regulate the mtor pathway to control translation and cell growth in response to nutrient and growth factor stimuli. |
2005-09-01 |
2023-08-12 |
Not clear |
| Avi Sofer, Kui Lei, Cory M Johannessen, Leif W Ellise. Regulation of mTOR and cell growth in response to energy stress by REDD1. Molecular and cellular biology. vol 25. issue 14. 2005-09-01. PMID:15988001. |
we have recently identified the stress response redd1 gene as a mediator of tuberous sclerosis complex (tsc)-dependent mtor regulation by hypoxia. |
2005-09-01 |
2023-08-12 |
Not clear |
| Zhaohui Feng, Haiyan Zhang, Arnold J Levine, Shengkan Ji. The coordinate regulation of the p53 and mTOR pathways in cells. Proceedings of the National Academy of Sciences of the United States of America. vol 102. issue 23. 2005-07-27. PMID:15928081. |
moreover, the mechanisms by which p53 regulates mtor involves amp kinase activation and requires the tuberous sclerosis (tsc) 1/tsc2 complex, both of which respond to energy deprivation in cells. |
2005-07-27 |
2023-08-12 |
Not clear |
| Ewan M Smith, Stephen G Finn, Andrew R Tee, Gareth J Browne, Christopher G Prou. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. The Journal of biological chemistry. vol 280. issue 19. 2005-07-12. PMID:15772076. |
recent work demonstrated the importance of the tuberous sclerosis protein tsc2 for regulation of mtor by insulin. |
2005-07-12 |
2023-08-12 |
Not clear |
| Andrew R Tee, John Bleni. mTOR, translational control and human disease. Seminars in cell & developmental biology. vol 16. issue 1. 2005-06-22. PMID:15659337. |
recent studies reveal that the tuberous sclerosis complex (tsc)-1/2, pten, and lkb1 tumor suppressor proteins tightly control mtor. |
2005-06-22 |
2023-08-12 |
human |
| Laura S Harrington, Greg M Findlay, Richard F Lam. Restraining PI3K: mTOR signalling goes back to the membrane. Trends in biochemical sciences. vol 30. issue 1. 2005-03-03. PMID:15653324. |
this finding, together with earlier work, strongly suggests that a major form of negative feedback inhibition of pi3k results from activated growth signalling via mammalian target of rapamycin (mtor) and the p70 s6 kinase (s6k) - a pathway that could have consequences for the development of type 2 diabetes and tuberous sclerosis complex. |
2005-03-03 |
2023-08-12 |
Not clear |
| Ken Inoki, Michael N Corradetti, Kun-Liang Gua. Dysregulation of the TSC-mTOR pathway in human disease. Nature genetics. vol 37. issue 1. 2005-02-07. PMID:15624019. |
high levels of dysregulated mtor activity are associated with several hamartoma syndromes, including tuberous sclerosis complex, the pten-related hamartoma syndromes and peutz-jeghers syndrome. |
2005-02-07 |
2023-08-12 |
human |
| Jennifer A Chan, Hongbing Zhang, Penelope S Roberts, Sergiusz Jozwiak, Grajkowska Wieslawa, Joanna Lewin-Kowalik, Katarzyna Kotulska, David J Kwiatkowsk. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. Journal of neuropathology and experimental neurology. vol 63. issue 12. 2005-01-14. PMID:15624760. |
pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of tsc1 or tsc2 leads to mtor activation. |
2005-01-14 |
2023-08-12 |
Not clear |